B. Riley Wealth Advisors Inc. Has $344,000 Position in Moderna, Inc. (NASDAQ:MRNA)

B. Riley Wealth Advisors Inc. decreased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 14.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,229 shares of the company’s stock after selling 888 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Moderna were worth $344,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. State Street Corp boosted its stake in shares of Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares during the period. Wellington Management Group LLP boosted its stake in Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Moderna by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after acquiring an additional 19,819 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after acquiring an additional 178,939 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on MRNA shares. Leerink Partners reduced their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday, September 17th. TD Cowen reduced their target price on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. Jefferies Financial Group decreased their target price on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Finally, The Goldman Sachs Group decreased their price objective on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a report on Monday, September 16th. Four research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $79.50.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,379 shares of company stock valued at $158,195 in the last quarter. 15.70% of the stock is currently owned by insiders.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $39.39 on Friday. The company has a fifty day moving average price of $46.43 and a 200 day moving average price of $80.38. Moderna, Inc. has a 1-year low of $35.80 and a 1-year high of $170.47. The firm has a market cap of $15.16 billion, a PE ratio of -6.77 and a beta of 1.58. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same period in the prior year, the firm earned ($1.39) earnings per share. Moderna’s revenue for the quarter was up 3.8% compared to the same quarter last year. Research analysts predict that Moderna, Inc. will post -9.3 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.